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Available online 9 August 2013Abstract Hematopoietic stem cells (HSC) 1 supply organisms with life-long output of mature blood cells. To do so, the HSC
pool size has to be maintained by HSC self-renewing divisions. PRDM3 and PRDM16 have been documented to regulate HSC
self-renewal, maintenance and function. We found Prdm11 to have similar expression patterns in the hematopoietic stem and
progenitor cell (HSPC) compartments as Prdm3 and Prdm16. Therefore, we undertook experiments to test if PRDM11 regulates
HSC self-renewal, maintenance and function by investigating the Prdm11−/− mice. Our data shows that phenotypic HSPCs are
intact in bone marrow (BM) of one-year-old Prdm11−/− mice. In addition, Prdm11−/− mice were able to fully regenerate the
hematopoietic system upon BM transplantation (BMT) into lethally irradiated mice with a mild drop in lymphoid output only.
Taken together, this suggests that PRDM11, in contrast to PRDM3 and PRDM16, is not directly involved in regulation of HSPCs in
mice.
© 2013 Elsevier B.V. All rights reserved.The PRDM family is characterized by the presence of aIntroduction
The hematopoietic system relies on constant replenishment of
mature cells from the HSC compartment. In order to maintain
tissue homeostasis, HSCs are tightly regulated by both intrinsic
and extrinsic signals (Warr et al., 2011).⁎ Corresponding author at: Faculty of Health Sciences, University of Co
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http://dx.doi.org/10.1016/j.scr.2013.07.009PR-domain that has similarities with the SET domain of histone
methyl transferases. The PR-domain is followed by repeated
zinc finger motifs in all members of the PRDM family with the
exception of PRDM11 that has a zinc knuckle that probably is
involved in protein–protein interactions (Briknarova et al.,penhagen, The Finsen Laboratory, Rigshospitalet Ole Maaløesvej, 5
ell (HSPC), bone marrow (BM), bone marrow transplantation (BMT),
enitor (MPP), pre-megakaryocyte/erythroid (preMegE), megakaryo-
yte/macrophage progenitors (GMP), common lymphoid progenitors
lony forming unit megakaryocyte (CFU-Mk), colony forming unit
Sca1+, c-Kithi).
1130 L.A. Thoren et al.2011; Fog et al., 2012). Several members of the PRDM family
have been shown to be important in regulation of the HSC
compartment and to be linked to hematological malignancies.
Hematopoietic-specific knockout of PRDM16 results in reduced
numbers of phenotypic and functional HSCs due to increased
apoptosis and cell cycle activity (Aguilo et al., 2011; Chuikov et
al., 2010). In contrast, overexpression of Prdm16 in HSCs causes
an expansion of HSCs in vitro that upon transplantation
generates amyeloproliferative disorder (Deneault et al., 2009).
PRDM3/EVI1–MDS1/MECOM is the fusion protein created by
intergenic splicing of EVI1 with MDS1 (Fears et al., 1996). It was
recently suggested to be responsible for the impairment in HSC
functions previously documented to be caused by EVI1 alone
(Zhang et al., 2011), although this is still debated (Kataoka et
al., 2011). EVI1 alone has been shown to play an important role
in both fetal and adult hematopoiesis and has proved important
for the survival, maintenance and proliferation of HSPCs inmice
(Goyama et al., 2008; Kataoka et al., 2011). High expression of
EVI1 in acute myeloid leukemia (AML) patients is associated
with poor prognosis. RPN1 is a fusion partner found upstream of
EVI1 in AML patients (Suzukawa et al., 1994) and RPN1–EVI1
was in the latest WHO classification of hematopoietic and
lymphoid neoplasms included as a new separate group (WHO
Classification of Tumours of Haematopoietic and Lymphoid
Tissues, Fourth Edition, 2008). RPN1 has also been reported to
translocate to other members of the PRDM family like PRDM16
(Duhoux et al., 2012), PRDM3 (Suzukawa et al., 1994) and
interestingly, translocation to PRDM11 has also been reported
(Lugthart et al., 2010).
Despite the striking effects on hematopoiesis of other
PRDM-family members, very little is known about the potential
function of PRDM11 within the hematopoietic system. We
therefore took advantage of the Prdm11−/− mouse line to
investigate the role of PRDM11 in the HSPC compartment.
Material and methods
Mice
The Prdm11−/− mice will be described elsewhere (manuscript
in preparation). Briefly, Prdm11 exons 2 and 3 were targeted
by loxP sites and excised using a germline CMV-cre mouse and
then backcrossed more than 10 generations onto C57BL/6
(CD45.2). WT mice B6.SJL (CD45.1) were used for transplan-
tation studies as recipients and support.
Phenotypic and cell cycle analysis of the bone
marrow
BM cells from femur and tibia were prepared into single cell
suspension and stained with the appropriate antibodies and
nucleic acid stains (for details on fluorescent conjugate, clone
and company see Supplemental Table 1). For cell cycle analysis,
BM cells from femur and tibia were prepared into single cell
suspension and stained with primary antibodies (SupplementalFigure 1 Phenotypic analysis of bone marrow sub-populations of
and WT controls was phenotypically analyzed by FACS. Represent
numbers were calculated for B) HSCs, C) MPPs, D) preMegEs, E) Mk
Flt3+. Horizontal bar indicates mean value. n = 8.Table 1) and subsequently fixed using 2% paraformaldehyde
(Sigma-Aldrich). Cells were next permeabilized with 0.01%
saponin (AppliChem) and stained with intracellular Ki67 (B56,
BD) antibody when appropriate. Finally, cells were stained with
DAPI (Invitrogen). All FACS analysis was done on the LSRII (BD).
Bone marrow transplantation
For Competitive BMT experiments, donor (CD45.2) and
competitor (CD45.1) cells were mixed in a 1:1 ratio and
transplanted into 10–12 week-old lethally irradiated (900
rads) recipients (CD45.1). Peripheral blood (PB) was collected
at indicated time points, red blood cells lysed with PharmLyse
(BD) and remaining white blood cells were stained with the
appropriate antibodies (anti-mouse CD45.1, CD45.2, CD4, CD8,
NK1.1, Mac1 and CD19, for details see Supplemental Table 1)
and analyzed by FACS. All FACS analyses of PB were run on the
LSRII (BD) and data analysis was performed using FlowJo
(TreeStar). Experiments were approved by the
“Dyreforsogstilsynet” in Denmark.
qRT-PCR
The Lineage−, Sca1+, c-Kithi (LSK), MkP and CLP Flt3+ cells
were sorted using similar gating strategies as depicted in
Fig. 1A. We defined B cells by the expression of B220 and T
cells by expression of CD4 and CD8. Cells of interest were FACS
sorted into RLT buffer containing 2-mercaptoethanol followed
by RNA extraction using RNeasy Micro Kit (Qiagen) according
to manufacturer's instructions. RNA was reverse transcribed
into cDNA using ProtoScript M-MuLV first strand cDNA synthesis
kit (NEB). Next, qPCR on cDNA from 200 cell equivalent using
Light Cycler 480 SYBR Green 1 Master (Roche) was run on a
Light Cycler 480 (Roche). Delta CT values were calculated by
2−(CT ‘Gene of interest’ − CT ‘House keeping gene’).
Primers used for qRT-PCR:
Prdm3 forward 5′-GCTATGATCAGCACAACCTTGTTG-3′
Prdm3 reverse 5′-TGCTGCCGTTCTTCGTGGATG-3′
Prdm11 forward 5′-TCATCCGACCCATCTATGGAC-3′
Prdm11 reverse 5′-TCAGCTGGCTTCTTCTCATGG-3′
Prdm16 forward 5′-GACCATACCCGGAGGTGTGT-3′
Prdm16 reverse 5′-GCGTCGGCTCCAAAGCTAAC-3′
B-actin forward 5′-CTCTTCCAGCCTTCCTTCCT-3′
B-actin reverse 5′-TGCTAGGGCTGTGATCTCCT-3′.
In vitro megakaryocyte colony assay and platelet
counts
Whole BM cells (100,000/culture slide) from WT or Prdm11−/−
mice were cultured using the MegaCult culture assay (StemCell
Technologies) according to manufacturer's instructions. The
following cytokines were added to the media: rh Throm-
bopoietin 50 ng/mL, rh IL-6 20 ng/mL, rh IL-11 50 ng/mL and
rm IL-3 10 ng/mL (PeproTech). After 7 days of culture, theWT and Prdm11−/− mice. A) BM of one-year-old Prdm11−/− mice
ative FACS plots with the average frequency shown. Absolute
Ps, F) preGMs, G) GMPs, H) preCFU-E, I) CFU-E/proE and J) CLP
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manufacturer's instructions.
Platelet levels in PB were measured using a Sysmex
KX-21N (Sysmex). All samples were measured in duplicates.Statistics
All data were screened for variance homogeneity using
Bartlett's test and the assumption of normality was assessed
by the D'Agostino and Pearson omnibus normality test.
Student's unpaired two tailed t-test was used when data
had a normal distribution with equal variance. Two sample
t-tests were used for comparison, adjusted by Welch
correction if the hypothesis of equal variances was rejected.
Mann–Whitney test was applied if data were not normally
distributed.Results and discussion
PRDM11 is dispensable for steady-state maintenance
of the hematopoietic system
To explore the expression pattern of Prdm11 within the
HSPC compartment we took advantage of the HemaExplorer
web server (http://servers.binf.ku.dk/hemaexplorer)
(Bagger et al., 2012; Bagger et al., 2013) and found that
Prdm3, Prdm16 and Prdm11 show similar expression pat-
terns in the HSPC compartments. All three transcripts
displayed high expression in the HSCs and were progressively
down-regulated following maturation (Supplemental Figs.
1A–C). To investigate if PRDM11 plays an important role in
maintaining the HSPC compartment during steady-state
hematopoiesis we phenotypically analyzed BMs of
one-year-old Prdm11−/− mice by flow cytometry (Pronk et
al., 2007). Despite the expression profile of Prdm11 we
observed no differences in either frequency or absolute
numbers of phenotypically defined HSCs and multipotent
progenitors (MPPs) between WT and Prdm11-/- animals (Figs.
1A–C) suggesting that PRDM11 is dispensable for the mainte-
nance of the earliest HSPCs duringsteady-state hematopoiesis.
Analysis of the further downstream progenitors, including
pre-megakaryocyte/erythroid progenitors (preMegEs), mega-
karyocytic progenitors (MkPs), pre-granulocyte/macrophage
progenitors (preGMs), granulocyte/macrophage progenitors
(GMPs) as well as Flt3+ common lymphoid progenitors (CLP
Flt3+), did not reveal any major differences in one-year-old
Prdm11−/− mice. Although we did observe a small decrease in
both frequency and absolute number of MkPs these data
suggests that PRDM11 is dispensable for early steady-state
myelopoiesis or lymphopoiesis (Figs. 1A, D–G, J). In addition,
the early erythroid progenitors pre-colony forming unit
erythroid progenitors (preCFU-Es) and CFU-E/proErythroidFigure 2 Cell cycle analysis of bone marrow sub-populations of
discriminate between G0, G1 and SG2M of indicated BM sub-po
Representative FACS plots with the average frequency shown. n =
between G0, G1 and SG2M in HSCs. Representative FACS plots with the
n = 3.progenitors (CFU/proEs) were unchanged in the Prdm11−/−
mice in comparison to WT controls (Figs. 1A, H–I). Similarly,
young 10–14 week-old Prdm11−/− mice do not differ from
their age matched WT controls either (data not shown).
Next, we investigated the cell cycle activity of HSPCs
within the BM since both PRDM3 and PRDM16 have previously
been implicated in HSC cell cycle control (Aguilo et al., 2011;
Chuikov et al., 2010; Zhang et al., 2011). Using flow
cytometry we were unable to detect any major differences
in the cell cycle distributions of HSPCs in the Prdm11−/−mice
as compared to WT controls except in the MPP, preMegE, MkP
and preCFU-E compartments where a marginal increase of
cells in SG2M was observed (Fig. 2A). This suggests that also
PRDM11, in addition to PRDM3 and PRDM16, is involved in the
regulation of progenitor cell proliferation, albeit mildly, but
restricted to the MPP, preMegE, MkP and preCFU-E compart-
ments. To investigate whether PRDM11 could be involved in
regulating HSC quiescence we also co-stained for Ki67 and
DAPI but found no difference in the distribution of cells
between G0 and G1 (Fig. 2B). This suggests that PRDM11 is not
directly involved in maintaining the balance between
quiescence and proliferation within the HSC compartment.
This notion is further supported by the previous finding that
PRDM11 deficiency does not affect the total number of cells in
any of the BM sub-compartments, with the exception of MkPs
(Fig. 1). Taken together, these data suggests that PRDM11 is
largely dispensable for steady-state maintenance of the
hematopoietic system in one-year-old mice with only a
marginal proliferative increase being observed in MPPs,
preMegEs, MkPs and preCFU-E.PRDM11 is dispensable for regeneration of the
hematopoietic system following transplantation
HSCs deficient of PRDM3 or PRDM16 were previously shown
to be unable to reconstitute the BM post-BMT (Aguilo et al.,
2011; Chuikov et al., 2010; Zhang et al., 2011). To evaluate
the regeneration capacity of HSCs from the Prdm11−/− mice
we performed competitive BMTs by mixing whole BM from
one-year-old Prdm11−/− or WT donors at 1:1 ratio with WT
competitor cells and transplanted them into lethally
irradiated recipients. Subsequently, we followed hemato-
poietic regeneration by FACS analysis of PB at 3, 8 and
16 weeks post-BMT. Initial short-term reconstitution at
3 weeks from Prdm11−/− donors did not differ in either
total reconstitution or any of the mature lineages investi-
gated (Figs. 3A–D). This suggests that PRDM11 is not
required for HSC homing, niche lodgement and initial
reconstitution. However, at 16 weeks post-BMT we observed
a mild reduction of total cells derived from the Prdm11−/−
donor that was due to decreases in mature B and T cells
(Figs. 3A,C–D). In contrast, the short-lived myeloid cells,
indicative of intact HSC function, were comparable with thatWT and Prdm11−/− mice. A) Cell cycle analysis using DAPI to
pulation in one-year-old Prdm11−/− mice and WT controls.
8. B) Cell cycle analysis using DAPI and Ki67 to discriminate
average frequency shown. Horizontal bars indicate mean value.
Figure 3 PRDM11 deficient mice regenerate the hematopoietic system post-bone marrow transplantation with a mild defect in
lymphopoiesis. Whole BM from one-year-old PRDM11 deficient (CD45.2; white square, black dashed line) or WT control mice (CD45.2;
black dot and line) was intravenously transplanted in 1:1 ratio (106:106 cells) with WT competitor cells (CD45.1) into lethally
irradiated WT recipient mice (CD45.1). PB was analyzed by FACS at 3, 8 and 16 weeks post-BMT and investigated for test cell derived
CD45.2+ A) % total reconstitution, B) % myeloid cells, C) % B cells, and D) % T cells. Four Prdm11−/− donor mice were assayed in 19 WT
recipient mice and 4 WT donors were assayed in 12 WT recipient mice. qRT-PCR of indicated FACS sorted sub-populations from WT
and Prdm11−/− mice for mRNA expression of E) Prdm11, F) Prdm3 and G) Prdm16 normalized to β-actin. Four individual mice per
genotype were investigated. Error bars indicate standard deviation. BDL = below detection level.
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derived myeloid cells at 8 weeks (Fig. 3B). In addition, we
also investigated the engraftment and regeneration capacity
of HSCs from 10–14 week-old Prdm11−/− donors by compet-
itive (Supplemental Fig. 2) and non-competitive (Supple-
mental Fig. 3) BMT, but found no difference in reconstitution
capacity in comparison with WT controls. In summary, our
data indicate that the HSCs from one-year-old Prdm11−/−
mice can regenerate the hematopoietic system post-BMT,
but that they are mildly impaired in their ability to fully
reconstitute the lymphoid lineage. It is tempting to
speculate that the impairment in lymphoid differentiation
happens downstream of the phenotypically intact CLP Flt3+
compartment. Taken together, in striking contrast to PRDM3
and PRDM16, our data suggest that PRDM11 is dispensable for
regeneration of the hematopoietic system following
transplantation.
We next speculated that compensatory up-regulation of
the expression of other PRDM family members such as PRDM3
and PRDM16 could potentially compensate for the loss of
PRDM11. We therefore tested the expression of Prdm3 and
Prdm16 in selected hematopoietic subsets but did not find
any evidence for transcriptional up-regulation of any of
these transcripts in the Prdm11−/− animals (Figs. 3F–G).
Whereas these findings clearly demonstrate that the mild
phenotype in the Prdm11−/− mice is not due to a compen-
satory increase in the expression of Prdm3 and Prdm16 they
do not exclude the possibility that the PRDM family members
may exert redundant functions in HSPCs. In line with this we
note that the lymphoid cells CLP Flt3+ B and T cells (as
opposed to the other cell types tested) are completely
devoid of both Prdm3 and Prdm16 expression, but do express
Prdm11, which potentially may explain the mild lymphoid
phenotype observed in Prdm11−/− animals (Figs. 3E–G).
PRDM11 is dispensable for megakaryocyte
development
From the HemaExplorer web server we found Prdm11 to be
expressed in MkP cells (Bagger et al., 2012; Bagger et
al.,2013). This was interesting since we observed a
significant downregulation of phenotypically defined MkPs
in the Prdm11−/− mice (Fig. 1E) that was further supportedFigure 4 PRDM11 is dispensable for in vitro megakaryocyte forma
potential in WT and Prdm11−/− whole BM cells. Data show mean numb
B) PB was sampled from WT and Prdm11−/− mice and analyzed for nby the mild proliferative increase observed in the same
population (Fig. 2A). This prompted us to further examine
the role of PRDM11 in megakaryocyte (Mk) development. To
do so we took advantage of the MegaCult cell culture
system to test the in vitro CFU-Mk potential of whole BM
cells from WT and Prdm11−/− mice, but found no difference
in either CFU-Mk or in a mix with granulocytes/macro-
phages CFU-GM/CFU-Mk mix colonies (Fig. 4A). To further
explore the Mk cell dependency on PRDM11 we analyzed PB
from both WT and Prdm11−/−mice for platelet numbers and
found no deviation in the capacity of the Mks to produce
platelets in the absence of PRDM11. Taken together, we
find very little evidence for PRDM11 being involved in the
development of Mks or in their ability to form platelets.
Conclusions
Prdm11 is highly expressed in the earliest HSPCs and is
downregulated following maturation. However, PRDM11 is
dispensable for the maintenance of the HSPCs during
steady-state hematopoiesis in one-year-old mice and is not
directly involved in maintaining the balance between
proliferation and quiescence. In addition, upon BMT
PRDM11 deficient cells were able to fully regenerate the
hematopoietic system long-term with only a minor drop in
lymphoid output suggesting that PRDM11 is not involved in
HSC engraftment and self-renewal. In conclusion, PRDM11 is
largely dispensable for maintenance and regeneration of the
hematopoietic system.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2013.07.009.
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